ArticleDie Naturwissenschaften2026
A tissue-to-blood mRNA classifier enables early detection of gastric cancer risk in precancerous lesions.
Article in Die Naturwissenschaften, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEarly identification of gastric cancer (GC) risk among patients with precancerous lesions remains a major clinical challenge. This study aimed to develop and validate a minimally invasive mRNA-based classifier for predicting malignant transformation.
methodsThree differentially expressed mRNAs (CCL3, CCL4, CXCL2) were identified through transcriptomic analyses of precancerous and cancerous gastric tissues and were further validated in tissue and serum samples. A logistic regression–based model which named risk signature assessment (RSA), was constructed using mRNA expression and key clinical variables.
resultsIn tissue biopsy samples from 229 patients, the RSA model achieved excellent predictive performance, with an AUC of 0.853 in the training set and 0.836 in the validation set. Sensitivity and specificity reached 82.6% and 79.7%, respectively. The RSA model outperformed clinical models (AUC = 0.695) and provided better net clinical benefit across thresholds. In serum samples (n = 210), the model remained robust, yielding an AUC of 0.846 in the training cohort and 0.843 in the validation cohort, with consistent sensitivity (81.3%) and specificity (77.1%). Risk reclassification improved markedly: low-risk patients identified by the RSA model had a cancer conversion rate of only 2.9% (vs. 4.3% using clinical models), while high-risk patients had rates of 12.9% (vs. 12.2%).
conclusionThis dual-platform mRNA classifier demonstrates strong potential for early, noninvasive identification of high-risk individuals with precancerous gastric lesions, offering a valuable tool for precision screening and clinical decision-making.
Indexed as
Identifiers
41880007What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.